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ABSTRACT
The crosstalk between immune cells, cancer cells, and extracellular vesicles (EVs) 
secreted by cancer cells remains poorly understood. We created three-dimensional 
(3D) cell culture models using human leiomyoma discs and Myogel to study the effects 
of immune cells on highly (HSC-3) and less (SCC-25) invasive oral tongue squamous 
cell carcinoma (OTSCC) cell lines. Additionally, we studied the effects of EVs isolated 
from these cell lines on the cytotoxicity of CD8+ T and NK cells isolated from three 
healthy donors. Our analysis included the effects of these EVs on innate immunity 
in zebrafish larvae. Activated immune cells significantly decreased the proliferation 
of both OTSCC cell lines and associated with a diminished invasion area of HSC-3 
cells. In general, EVs from SCC-25 increased the cytotoxic activity of CD8+ T and NK 
cells more than those from HSC-3 cells. However, this effect varied depending on the 
source and the immune and cancer cell subgroups. In zebrafish, the amount of IL-13 
mRNA was decreased by SCC-25 EVs. This study describes promising in vitro and in 
vivo models to investigate interactions between immune cells, cancer cells, and EVs.
INTRODUCTION
After the introduction of Coley’s toxin, “a 
suspension of the gram-negative bacteria,” as an activator 
of the immune system against cancer cells, researchers 
turned their attention to the role of the immune system 
in cancer research [1]. Subsequently, studies showed that 
the immune response to cancer may either suppress or 
support tumor growth depending on the type of immune 
effector mechanism activated. Based on these studies, 
immune cells can be broadly divided into “good/anti-
tumorigenic immune cells” represented by, for instance, 
Th1, CD8+T, NK, and M1 macrophages and “bad/pro-
tumorigenic immune cells” such as Th2, Treg, and M2 
macrophages [2].
In oral tongue squamous cell carcinoma (OTSCC), 
the most common type of head and neck cancer, a 
lymphocytic infiltrate was associated with a better 
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response to radiotherapy and an overall good prognosis 
[3]. More specifically, our group has already found a 
correlation between inflammatory cell infiltrates and 
OTSCC prognosis depending on these cell types [4]. That 
is, we found that patients with a tumor microenvironment 
(TME) rich in CD163+Foxp3+ CD80+ experience a higher 
rate of cancer recurrence compared to patients with TME 
low in CD163+Foxp3+ CD80+ [4].
Extracellular vesicles (EVs) or exosomes are small 
vesicles (30–100 nm) released from all cells [5] which 
carry various proteins, lipids, and nucleic acids (DNA, 
mRNA, and miRNA) and are found in biological fluids 
including saliva, blood, and cell culture media [6]. 
Interestingly, tumor cells were found to secrete more EVs 
than normal cells [7]. Thus, it became clear that cancer 
cells use EVs as a tool for distant communication with 
other cells, including TME, through the horizontal transfer 
of their active biomolecules. In fact, EVs seem to play 
an active role in the biology and clinical course of cancer 
by modulating the immune system and affecting the cell 
phenotype [8–10].
This study aimed to identify better in vitro TME 
matrix 3D models for co-culturing immune and cancer 
cells and to investigate the crosstalk between these cells. 
First, we discuss the effects of immune cells on the 
proliferation, migration, and invasion of OTSCC cells 
in vitro using human myoma discs and a soluble myoma 
matrix “Myogel” in 3D cell culture models. Then, we 
describe our analysis of the effects of EVs from OTSCC 
cells on the phenotype and cytotoxic activity of selected 
immune cells in vitro and on the innate immune system in 
vivo using a zebrafish model.
RESULTS
Association between activated peripheral blood 
mononuclear cells and OTSCC cell proliferation 
and invasion area in myoma discs
After co-culturing the peripheral blood mono-
nuclear cells (MNCs) with OTSCC cells in a 3D 
organotypic model, myoma discs were prepared for 
immunohistochemical staining for pan-cytokeratin and 
Ki67. In accordance with previous reports, HSC-3 cells 
showed a higher invasion ability compared with SCC-25 
cells (Figure 1A and 1B). No positive staining for pan-
cytokeratin was detected in myoma discs without cancer 
cells (Figure 1C). The percentage of Ki67+ cells was 
similar for HSC-3 and SCC-25 cells on the surface of the 
myoma, that is, cells had not invaded the discs (Figure 
1D and 1E). Similar to pan-cytokeratin, myoma discs 
without cancer cells were negative for Ki67 (Figure 1F). 
Figure 2A illustrates our co-culture model of the OTSCC 
cells and MNCs.
We found that activated MNCs reduced cancer 
cell proliferation (both HSC-3 and SCC-25, P=0.04 
and P=0.03, respectively). Yet, when CD3+ T cells were 
activated, the reduction effect was only found for SCC-25 
cells (P=0.002; Figure 2B).
In line with a decrease in cancer cell proliferation, 
the invasion area in the myoma discs was reduced 
when activated MNCs were added. This reduction was 
statistically significant for the HSC-3 cells (P=0.04), but 
not for SCC-25 cells, for which the invasion area was 
much less than for HSC-3 cells (Figure 2C).
Figure 1: Comparison of the invasion ability of HSC-3 SCC-25 cells. Myoma discs (with or without OTSCC cells) were stained 
with pan-cytokeratin and Ki67. HSC-3 showed a higher ability to invade compared to SCC-25 (A and B), while no staining was found in 
the myoma discs without cancer cells (C). The percentage of Ki67+ cells was similar for HSC-3 and SCC-25 cells (D and E); similar to 
pan-cytokeratin, the myoma discs without cancer cells were negative for Ki67 (F). Scale bar = 100 µm.
Oncotarget60125www.impactjournals.com/oncotarget
In addition, the invasion depth for both HSC-3 and 
SCC-25 cells was not affected by adding the peripheral 
blood MNCs (Figure 2D).
In both tongue cancer cell lines, cell proliferation 
positively correlated with the invasion area (r=0.5, 
P=0.002 for HSC-3; r=0.5, P=0.02 for SCC-25; 
Figure 2E), but not with invasion depth (r=0.2, P=0.1 for 
HSC-3; r=0.1, P=0.6 for SCC-25; Figure 2F).
Migration of peripheral blood MNCs toward 
OTSCC cells through myoma discs
To study the migration of peripheral blood MNCs 
toward OTSCC cells through the myoma discs, we stained 
myoma slides with CD45 (a common leukocyte antigen) 
and CD8 (a cytotoxic T cell marker). Because myoma tissue 
already has its own inflammatory cells, CD45+ and CD8+ T 
Figure 2: Effects of the peripheral blood MNCs on the OTSCC cell proliferation, invasion area, and invasion depth. 
Schematic of our co-culture model of cancer and immune cells (A). The percentage of Ki67+ cells were counted from at least three 
randomly selected fields (B). Invasion area (C) and invasion depth (D) were measured using the ImageJ software. Correlations between cell 
proliferation and invasion area (E) and invasion depth (F) were completed using the Pearson’s test. We used the one-way ANOVA followed 
by Tukey’s post-hoc test to determine statistical significance. *P ≤ 0.05, **P ≤ 0.01. All experiments were repeated independently four to 
eight times and each in duplicate.
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cells were counted and compared between different groups. All 
myoma discs used in this study originated from a single batch.
We found that CD45+ cells became more numerous 
in the myoma discs when activated MNCs were added 
(Figure 3A–3D). We found a similar trend for CD8+ T 
cells, primarily at the bottom of the myoma discs around 
the blood vessels (Figure 3E–3H).
In addition, CD45+ cells increased in the activated 
MNCs group across nearly all experiments; however, this 
finding was not statistically significant due to fluctuations 
in the number of CD45+ cells from one sample to another 
(Figure 3I and 3J).
Yet, the increase in CD8+ T cells was statistically 
significant in the presence of highly invasive HSC-3 cells 
(P=0.02), but not for less invasive SCC-25 cells (P>0.05; 
Figure 3K and 3L).
Adding MNCs without CD3 and CD28 antibodies 
or phorbol 12-myristate 13-acetate (PMA) and ionomycin 
appeared insufficient to prompt the migration of peripheral 
blood MNCs toward OTSCC cells (Figure 3I–3L).
The effect of peripheral blood MNCs on the 
migration of OTSCC cells on Myogel
We used a co-culture of the peripheral blood 
MNCs with HSC-3 and SCC-25 cells in 96-well plates 
coated with Myogel to test whether the presence of 
peripheral blood MNCs affects the migration of cancer 
cells (Supplementary Video 1). We found that peripheral 
blood MNCs exerted no effect on the migration of HSC-
3 or SCC-25. Primary inhibition was achieved by adding 
MNCs with PMA and ionomycin. However, PMA and 
ionomycin alone also appeared to inhibit migration 
(Supplementary Figure 1).
The effect of EVs from OTSCC cells on human 
primary macrophage polarization
We differentiated human primary monocytes to 
macrophages for seven days using a macrophage-colony 
stimulating factor (M-CSF; Supplementary Figure 2A).
Macrophages were incubated for 24 hours with 
the HSC-3 and SCC-25 EVs and polarized to M1 using 
lipopolysaccharide (LPS) and interferon gamma (IFN-γ) 
and M2 using interleukin (IL)-4 and IL-13 as the positive 
controls. M1 macrophages were rounded, while M2 
macrophages were more cone-shaped. We found that 
macrophages incubated with HSC-3 and SCC-25 EVs 
were primarily similar to spindle-shaped M0 with some 
cells exhibiting the M2-representative cone-shaped 
morphology (Supplementary Figure 2B). To study the 
effect of the OTSCC cell EVs on macrophage polarization, 
Figure 3: Migration of peripheral blood MNCs toward OTSCC cells through myoma discs. Slides from the myoma discs 
were stained with CD45 (A-D) and CD8 (E-H), images presented are from our HSC-3 experiment. The number of CD45+ (I, J) and CD8+ T 
cells (K, L) were calculated from at least three selected fields (10 or 20X magnification) showing the highest infiltration for each slide. We 
used the one-way ANOVA followed by Tukey’s post-hoc test to determine statistical significance. *P ≤ 0.05. All experiments were repeated 
independently four to eight times and each in duplicate. Scale bar = 100 µm.
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we used quantitative real-time PCR for the M1 (CXCL9 
and CXCL10) and M2 (CCL17, CCL18, and CCL22) 
markers.
Macrophages incubated with HSC-3 and SCC-25 
EVs exhibited no difference from controls for any of the 
M1 and M2 markers (Supplementary Figure 2C). As a 
positive control, a macrophage stimulated with LPS and 
IFN-γ strongly expressed the M1 markers (CXCL9 and 
CXCL10), while the macrophages stimulated with IL-4 
and IL-13 highly expressed the M2 markers (CCL17, 
CCL18, and CCL22; Supplementary Figure 2C).
EVs from OTSSC cells modulate the cytotoxic 
activity of CD8+ T and NK cells
We isolated human primary CD8+ T and NK cells 
from three healthy donors and incubated them with HSC-
3 or SCC-25 EVs for 24 hours. Then, we added CD8+ T 
and NK cells to HSC-3 and SCC-25 cells to study their 
cytotoxic activity (Supplementary Video 2 and 3).
In general, HSC-3 and SCC-25 EVs increased the 
cytotoxic activity of CD8+ T and NK cells (Figure 4). 
However, this effect varied, depending upon several factors 
Figure 4: The effects of the EVs from OTSCC cells on the cytotoxic activity of CD8+ T and NK cells. An immune killing 
assay was used to study the effect of OTSCC cell EVs on the cytotoxic activity of CD8+ T and NK cells. CD8+ T and CD56+ NK cells were 
isolated from the buffy coat of three healthy donors and incubated with media alone, HSC-3 EVs or SCC-25 EVs, for 24 hours. CD8+ T 
and NK cells were then incubated with HSC-3 and SCC-25 cells for five days and the number of apoptotic cells were counted over time.
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including the following: the source of the immune cells 
(cells from different donors showed different responses to 
cancer cell exosomes), the source of EVs (from HSC-3 or 
SCC-25 cells), the type of affected cancer cells (HSC-3 
or SCC-25 cells), and the type of immune cells (CD8+ T 
or NK cells). The cytotoxic activity of the CD8+ T cells 
from donor 1 increased due to SCC-25 EVs when added 
to HSC-3 but not SCC-25 cells (Figure 4A and 4D). For 
donor 2, HSC-3 EVs appeared most effective, but only 
against HSC-3 (Figure 4B and 4E). For donor 3, both 
HSC-3 and SCC-25 EVs increased the cytotoxic activity 
of CD8+ T cells against both HSC-3 and SCC-25 cells 
(Figure 4C and 4F).
For NK cells, HSC-3 and SCC-25 EVs did not 
induce the cytotoxic activity of NK cells from donor 1 
(Figure 4G and 4J). For donor 2, SCC-25, but not HSC-
3 EVs, enhanced the cytotoxic activity of NK cells 
against both HSC-3 and SCC-25 cells (Figure 4H and 
4K). Furthermore, NK cells from donor 3 induced more 
apoptosis in the HSC-3 cells when incubated with HSC-3 
and SCC-25 EVs, while this ability against SCC-25 only 
appeared when incubated with SCC-25 EVs (Figure 4I 
and 4L).
We also noted an inhibition of the cytotoxic activity 
of CD8+ T and NK cells in three cases (Figure 4D, 4G, and 
4J). In two of these cases, SCC-25 EVs resulted in this 
effect, while the third stemmed from HSC-3 EVs.
Finally, we found that EVs from less aggressive 
SCC-25 cells more effectively enhanced the cytotoxic 
activity of immune cells in 7 of 12 cases (Figure 4A, 4C, 
4F, 4H, 4I, 4K, and 4L), while EVs from more aggressive 
HSC-3 cells induced an immune activity in only 4 of 12 
cases (Figure 4B, 4C, 4F, and 4I).
The effect of EVs from OTSCC cells on the 
innate immune system of zebrafish
We injected HSC-3 and SCC-25 EVs into the 
blood circulation of zebrafish larvae at 48 hours post-
fertilization, and then stored the larvae for 24 hours before 
collecting RNA to analyze the expression of selected pro- 
and anti-inflammatory cytokines.
The levels of TNF-α and IFN-γ mRNA were 
undetectable across all groups (data not shown). IL-1β, 
IL-4, TGF-β1a, and IL-10 mRNA levels were unaffected 
by cancer cell EVs (Figure 5A–5D). However, SCC-25 
steadily diminished the IL-13 mRNA level to one-third 
(Figure 5E).
DISCUSSION
This study provides an in vitro 3D human TME 
matrix model in which immune cells were co-cultured 
with cancer cells on human uterus leiomyoma tumor 
discs or a soluble myoma matrix. These novel methods 
were designed to provide a more realistic simulation of 
the human TME than previously described in vitro models 
primarily using the mouse Engelbreth-Holm-Swarm 
tumor matrix, Matrigel, or rat-tail collagen [11, 12]. The 
study here shows the ability of immune cells to influence 
cancer cell proliferation and invasion in 3D models. It also 
highlights the importance of cancer cell EVs in enhancing 
Figure 5: The effects of the OTSCC cell EVs on the pro- and anti-inflammatory cytokines in a zebrafish larvae model. 
Zebrafish larvae were injected with PBS (control), HSC-3 EVs, and SCC-25 EVs and left for 24 hours. We measured the mRNA expression 
for IL-1β, (A) IL-4, (B) TGF-β1a, (C) IL-10, (D) and IL-13 (E) using q-PCR. Twenty five larvae were injected in each group and each 
experiment was repeated 3 times independently.
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the cytotoxic activity of immune cells and the expression 
of some anti-inflammatory cytokines using a zebrafish 
larvae model.
Studying the interaction between immune and 
tumor cells poses challenges since cancer cells in solid 
tumors are adherent, while most immune cells are non-
adherent rendering their co-culture difficult. Furthermore, 
the co-culture environment is not representative of in vivo 
conditions when completed on plastic. Our in vitro model 
relies on human hypoxic myoma discs, which exhibit 
superior features in studying cancer cell invasion over 
classic organotypic models [11, 13]. In a myoma disc 
model, we seeded cancer cells on top of discs, whereas 
immune cells were added below to evaluate cancer 
cell chemotaxis towards immune cells. This effect was 
simultaneously mild and selective. In the majority of 
experiments, adding activated MNCs (with PMA and 
ionomycin) increased the number of CD45+cells in the 
myoma discs. However, we found substantial variation 
between samples. In fact, the attraction of CD8+ T cells 
appeared more distinct since their number increased 
significantly only in the HSC-3 myoma experiments. 
This indicates a selectivity among cancer cells to attract 
MNCs. However, CD8+ T cells were primarily found at 
the bottom and around the blood vessels of myoma discs. 
This suggests that MNCs use myoma disc blood vessels, 
as well as the inability of these cells to travel from the 
bottom towards superficial cancer cells. This may result 
from a weaker chemotaxis signal from the surface cancer 
cells compared to the chemokines produced by other 
bottom MNCs [14]. Alternatively, this may result from 
the loss of inflammatory vascular responses, including 
altering vascular permeability and oncotic pressure. These 
factors control the accumulation of fluids, molecules, and 
inflammatory cells and play crucial roles in the initial steps 
of chemotaxis and inflammation [15, 16]. Increase in the 
number of CD8+T cells was associated with the decrease 
in the cancer cells proliferation and their invasion area. 
Our results are in line with others who showed positive 
correlation between the number of the CD8+T cells and the 
survival time of the oral cancer patients [17, 18].
In addition, our results revealed the importance 
of stimulatory signals in controlling the type and fate 
of immune responses against cancer cells, since non-
activated MNCs were unable to affect HSC-3 and SCC-
25 cells for any of the features we studied. The most 
significant effect we observed occurred when MNCs 
were activated using PMA and ionomycin, while CD3 
and CD28 antibodies showed a partial effect only on the 
proliferation of SCC-25 cells.
MNCs in general and lymphocytes in particular 
produce several soluble factors when subject to PMA and 
ionomycin treatment [19, 20]. Therefore, inhibiting cancer 
cell proliferation may result from soluble factors secreted 
from activated MNCs. Indeed, others found that soluble 
factors from embryonic and mesenchymal stem cells, for 
instance, can inhibit cancer cell proliferation [21–23]. 
The positive correlation between cancer cell proliferation 
and the invasion area indicates that a reduction in the 
proliferation area results from a decrease in cancer cell 
proliferation. Neither the invasion depth nor cancer cell 
migration were affected by activated MNCs. This may 
indicate an insignificant effect of activated MNCs on 
inhibiting cancer invasion and metastases formation [24]. 
Furthermore, cancer cell migration was only affected by 
PMA and ionomycin. A similar effect did not occur when 
these compounds were added to the media under myoma 
discs since they were not in direct contact with cancer 
cells. In both of our OTSCC cell lines, cell proliferation 
positively correlated with the invasion area, but not with 
the invasion depth, indicating that more cancer cells do 
not necessarily lead to a higher probability of invasion and 
metastases [24].
Because cancer cell EVs are known to significantly 
affect cells in TME [25], the second part of this study 
focused on cancer cell EVs on the immune system. We 
analyzed the effect of cancer cell EVs on macrophage 
polarization, CD8+ T and NK cell cytotoxicity, and the 
innate immune system in vivo using a zebrafish model. 
M2 (tumor-associated) macrophages, when present in 
TME, correspond with a poor prognosis in several cancers, 
including tongue cancer [4, 26, 27]. Cancer cells through 
the conditioned media can polarize primary macrophages 
and the human monocytic cell line (THP-1) towards M2 
[28, 29]. We investigated whether this polarization effect 
could also be achieved using cancer cell EVs. While our 
pilot experiment using THP-1 cells incubated with HSC-3 
EVs indicated a clear shift towards M2 (data not shown), 
we did not obtain similar results when we tested primary 
human macrophages. The difference between cancer 
cell–conditioned media and their EVs vis-à-vis affecting 
macrophage polarization may result from isolated EVs 
being too weak compared with the complete conditioned 
media, which is rich with cytokines and growth factors 
needed for macrophage polarization. These differences in 
the responses between THP-1 and primary macrophages 
agree with previous reports demonstrating that the THP-1 
cell line is more responsive to stimulants compared with 
primary monocytes [30]. Therefore, THP-1 results may 
not accurately represent results of the primary cells.
Cancer and dendritic cell EVs can be used to 
activate the immune system against cancer through a 
mechanism similar to that in vaccines [31]. Here, we 
isolated EVs from more and less aggressive OTSCC cell 
lines (HSC-3 and SCC-25, respectively) and incubated 
them with adaptive immunity CD8+ T cells and innate 
immunity NK cells followed by immune cell co-culturing 
with OTSCC cell lines. Interestingly, the CD8+ T and NK 
cell responses to cancer cell EVs varied depending on 
several factors. The cytotoxic activity of the immune cells 
fluctuated depending on the donor immune cells, OTSCC 
cell line EVs, and against which OTSCC cells tested. Our 
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results reflect the immune system fluctuations from person 
to person based on both genetic and epigenetic factors. 
This agrees with a review by Kunigelis et al. [31], who 
concluded that tumor EVs can exert contradictory effects 
(activating and inhibiting) on immune cells such as 
macrophages, CD4+ and CD8+ T cells, and dendritic cells. 
This presents a challenge to the use of EVs for clinical 
purposes.
Zebrafish increasingly serve as a model for 
studying cancer, particularly the crosstalk between 
cancer cells and the immune system [32, 33]. Like other 
non-mammalian model organisms, the zebrafish model is 
efficient, economical, and ethical. It also provides a fully 
developed vertebrate immune system closely resembling 
mammalian immunity given the similarities of the innate 
immune system of zebrafish to the mammalian system. 
In addition to that, all immune cell types are shared, 
including the neutrophils, macrophages, monocytes, 
dendritic cells, basophils, mast cells, and eosinophils 
[34–36]. The basic ethical principle guiding the model 
organism choice is to choose the one suitable for 
answering the research question and with the lowest 
degree of neurophysiological sensitivity. We chose the 
zebrafish larval model because it not only appears highly 
suitable, but also represents the most ethical model for 
this study. In order to understand the effect of cancer 
cell EVs on the innate immune system, we studied 
several pro- and anti-inflammatory cytokines. Cytokines 
represent major players in cancer progression, first 
through their direct effect on cancer cells, and second 
through their effect on TME, particularly immune cells 
[35]. Anti-inflammatory cytokines typically associate 
with a poor prognosis, primarily due to their inhibitory 
effect on the immune system [38, 39].Our results 
indicated that HSC-3 and SCC-25 EVs were unable to 
alter pro-inflammatory cytokine expression. By contrast, 
cancer cell EVs decreased the level of IL-13, an anti-
inflammatory cytokine. In fact, our results are not in 
line with a previous report that showed an increase in 
the level of IL-13 in the saliva of OSCC patients [38]. 
This indicates that not all elements of TME, including 
cancer cell EVs, induce the same direct effect on the 
innate immunity.
Taken together, our results along with previous 
reports support the need for a personalized approach 
to cancer treatment. This treatment should be based 
on testing the chemoradiation options available using 
a patient’s cancer cells supplied with patient’s serum, 
containing, for instance, EVs and cytokines. This test 
should consist of a 3D organotypic model instead of 
conventional 2D cell cultures on plastic. Compared to 
previousin vitro models, our 3D human TME-simulating 
models permit us to combine cancer cells with several 
cancer-associated cell types (such as immune cells) and 
soluble factors (including EVs) to better represent the 
complexity of solid cancers.
MATERIALS AND METHODS
Isolation of the human peripheral blood MNCs 
from the buffy coat of healthy donors
Human peripheral blood MNCs were isolated from 
a buffy coat provided by the Finnish Red Cross. A density 
gradient technique was followed to isolate MNCs using 
Ficoll–Paque PLUS (GE Healthcare, Piscataway, NJ, 
USA).
A MACS system (Miltenyi Biotec, Bergisch 
Gladbach, Germany) with a negative selection was used 
to isolate CD8+ T cells, CD14+ monocytes, and CD56+ 
NK cells from the peripheral blood MNCs of three healthy 
donors according to the manufacturer’s protocol.
To check the purity of the isolated cells, different 
cell populations were stained using a panel of antibodies. 
This panel included anti-CD3-APC, anti-CD8-PerCP-
Cy5.5, anti-CD14-FITC, and anti-CD56-PE (BD 
Biosciences, San Jose, CA, USA). Stained cells were 
acquired with FACS–Verse and analyzed using the BD 
FACSuite™ software.
CD3+ CD8+ T cells, CD3- CD14+ monocytes, and 
CD3- CD56+ NK cells formed 96%, 92%, and 92%, 
respectively, of the selected population (Supplementary 
Figure 3).
Cell culture of human OTSCC cells
Two human OTSCC cell lines, HSC-3 (Japan Health 
Sciences Foundation, Japan) and SCC-25 (American Type 
Culture Collection, Manassas, VA, USA), were used in 
this study. HSC-3 cells were highly invasive, while SCC-
25 cells were poorly invasive [40]. The cells were cultured 
in 75 cm2 flasks containing Dulbecco’s modified Eagle’s 
medium (DMEM)-12 (Gibco, Paisley, UK) supplied with 
10% heat-inactivated fetal bovine serum (FBS), 100 U/ml 
penicillin, 100 μg/ml streptomycin, 250 ng/ml fungizone, 
and 50 μg/ml ascorbic acid.
Co-culture of human peripheral blood MNCs 
with human OTSCC cells using organotypic 
myoma discs
In order to study the effect of peripheral blood 
MNCs on the proliferation and invasion of OTSCC 
cells and the ability of cancer cells to attract MNCs, we 
developed an in vitro model using human uterine myoma 
discs. The Ethics Committee of Oulu University Hospital 
approved our use of myoma tissue and all patients signed 
an informed consent form. We prepared uterine myoma 
discs and completed invasion experiments with some 
modifications as described previously [11]. Myoma discs 
do not have any live cells since they all die during the 
preparation process [41]. In brief, we placed myoma discs 
into Transwell® inserts (Corning Inc., Corning, NY, USA) 
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and 50 × 104 HSC-3 and SCC-25 cells were seeded on top 
of the discs. The cells were allowed to adhere overnight, 
and, on the next day, the discs were transferred onto a steel 
grid in a 12-well plate supplied with 1.2 ml culture media 
replaced every 3 to 4 days for 10 days. On the fourth day, 
20 × 105 MNCs were added under the myoma discs either 
alone (non-activated), with 2 µg/ml CD28 antibody (BD 
Bioscience) in a well coated with 5 µg/ml CD3 antibody 
(BD Bioscience, to activate CD3+ T cells) or with 
5 ng/ml PMA (Sigma Aldrich, St. Louis, Mo, USA,) and 
1 µM ionomycin (BD Bioscience, to activate all MNCs). 
For controls, cancer cells were cultured either with media 
alone or with media supplied with 5 ng/ml PMA and 1 µM 
ionomycin.
Immunohistochemical staining of the myoma 
discs
Myoma discs were fixed in 10% formalin and 
embedded in paraffin blocks. All samples were cut into 
6-µm-thick sections and stained using a fully automated 
Leica BOND-MAX staining robot (Leica Microsystems, 
Wetzlar, Germany) and a horseradish peroxidase–labeled 
dextran polymer method. As primary antibodies, we 
used monoclonal mouse anti-human pan-cytokeratin 
(0.7 µg/ml), Ki67 (0.8 µg/ml), CD45 (0.94 µg/ml), and 
CD8 (3 μg/ml; all from DAKO, Glostrup, Denmark).
Scratch-wound cell migration assay
To test the effect of peripheral blood MNCs on 
OTSCC cell migration in a 3D cell culture, wells of a 
96-well Imagelock plate (Essen Bioscience, Ann Arbor, 
MI, USA) were coated with 300 µg/ml Myogel, a matrix 
derived from human myoma tissue to replace Matrigel®, 
of mouse origin [12], and left overnight in the cell culture 
incubator. Excess Myogel was removed by suction and 
HSC-3 and SCC-25 cells were seeded at a density of 
30 × 103 cells/well and left to adhere overnight. We used 
the WoundMaker™ (Essen Bioscience) tool in order to 
achieve homogeneous scratch wounds. After making the 
wound, the media was replaced with 100 µl of fresh media 
and 80 × 103 MNCs with or without stimulants (as in the 
organotypic model) were added. As a control, cancer 
cells were cultured with either media alone or with media 
supplied with 5 ng/ml PMA and 1 µM ionomycin. Wound 
confluence was monitored using the IncuCyte Live-Cell 
Imaging System (Essen Bioscience), and images were 
taken each hour.
EV isolation and characterization
HSC-3 and SCC-25 cells were seeded at a density 
of 1.3 × 106 per 75 cm2 flask and left to adhere overnight. 
The cell culture media was removed and the flasks were 
washed with phosphate buffered saline (PBS) before 
adding the serum-free DMEM-12 media. Cells were 
cultured for 48 hours and the media was then collected 
for EV isolation.
EVs were isolated using a two-step 
ultracentrifugation procedure. First, the conditioned media 
was centrifuged at 10 000 × g for 90 min at 4°C. The 
supernatant was then collected and centrifuged again at 100 
000 × g for 90 min at 4°C. The second supernatant was 
discarded and the pellet containing EVs was re-suspended 
in 200 µl of PBS and kept at –80°C until further use.
Purified EV samples were analyzed by nanoparticle 
tracking analysis (NTA) using Nanosight model LM14 
(Nanosight) equipped with a blue (404 nm, 70 mW) 
laser and scientific CMOS camera. The samples were 
diluted in Dulbecco’s PBS and three 90-s videos were 
recorded using camera level 14. The data were analyzed 
using NTA software version 3.0 with the detection 
threshold optimized for each sample and the screen gain 
at 10 to track as many particles as possible with minimal 
background.
For immuno-electron microscope of the complete 
mount of EV samples, EVs were loaded on 200 mesh 
grids and fixed with 2% PFA. The samples were blocked 
with 0.5% BSA, in a 0.1-M NaPO4 buffer (pH 7.0) for 
10 min and stained with anti-CD63 (Pelicluster, Sanquin, 
Amsterdam, The Netherlands) as well as 10-nm gold-
conjugated anti-mouse secondary antibodies in 0.1% BSA 
in the same buffer for 30 to 60 min at room temperature. 
EVs were washed extensively before negative staining 
with 2% neutral uranyl acetate and embedded in a methyl 
cellulose–uranyl acetate mixture (1.8/0.4%). Samples 
were imaged using Tecnai 12 (FEI Company, Eindhoven, 
The Netherland) at 80 kV equipped with a Gatan Orius 
SC 1000B CCD camera (Gatan Inc. USA) using a 4008 × 
2672 pixel image size and no binning.
The majority of EVs fell within the range of 50 to 
100 nm and were CD63+ (Supplementary Figure 4).
Monocyte differentiation and macrophage 
polarization
Human primary CD14+ monocytes were isolated 
from a buffy coat and tested for purity using flow 
cytometry. Monocytes were seeded at a density of 20 × 
104 in a 24-well plate. The culture medium was advance 
RPMI-1640 (Gibco) supplied with 10% FBS, 1% 
L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 250 ng/ml fungizone. The cells were allowed to adhere 
for 90 min, and unattached cells were then washed away 
with PBS and the wells were supplied with fresh media 
plus 100 ng/ml M-CSF (R&D Systems, Minneapolis, 
MN, USA). Monocytes were allowed to differentiate into 
macrophages for seven days, and images were taken each 
day using a Nikon DS-Fi2 camera (Nikon, Tokyo, Japan).
To study the effect of cancer cell EVs on 
macrophage polarization, differentiated macrophages were 
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then subjected to EVs isolated from HSC-3 and SCC-25 
cells for 24 hours. As a positive control, macrophages were 
differentiated to M1 macrophages using 10 ng/ml LPS 
(Sigma-Aldrich) and 20 ng/ml IFN-γ (Prospec, Rehovot, 
Israel), and to M2 macrophages using 20 ng/ml IL-4 and 
20 ng/ml IL-13 (Prospec).
To check macrophage phenotypes using q-PCR, 
cells were lysed using an RLT buffer (Qiagen, Düsseldorf, 
Germany) and kept at –80°C until RNA isolation.
Immune cell killing assay
The cytotoxic activity of CD8+ T and NK cells 
was tested against OTSCC cells using an immune cell 
killing assay. HSC-3 and SCC-25 cells were labeled 
with fluorescent dye using a CellTrace™ Far Red Cell 
Proliferation Kit (Invitrogen, Carlsbad, CA, USA), seeded 
at a density of 5000 cells in a 96-well plate and left to 
adhere overnight. CD8+ T and NK cells were cultured 
either with media alone or with media supplied with HSC-
3 and SCC-25 EVs for 24 hours. As activators, CD8+ T 
cells were activated by 100 ng/ml CD3 antibody and 10 
ng/ml IL-2 (eBioscience, San Diego, CA, USA), while 
for NK cells only we used 10 ng/ml IL-2. Next, 50 × 103 
NK and CD8+ T cells were added to the cancer cells (10:1 
ratio) in the presence of 2.5-µM IncuCyte™ Caspase-3/7 
Apoptosis Assay Reagent (Essen Bioscience). The plate 
was placed in the IncuCyte Live-Cell Imaging System for 
five days and images were taken every two hours.
Microinjection of EVs into zebrafish larvae
Wild-type zebrafish of the AB strain were 
maintained at 28.5°C as described previously [42]. The 
larvae were grown at +28.5°C in an embryonic medium 
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM 
MgSO4, and 10–15% Methylene Blue; Sigma-Aldrich). 
At 48 hours post-fertilization, zebrafish larvae were 
dechorionated, anaesthetized with 0.04% Tricaine, and 
1 nl of HSC-3 or SCC-25 EVs or PBS was microinjected 
into the blood circulation valley (Duct of Cuvier). Larvae 
were transferred to a fresh embryonic medium and kept 
at +28.5°C for 24 hours and then collected for RNA 
isolation. Each group consisted of 25 larvae and each 
experiment was repeated 3 times independently.
Quantitative real-time PCR
Two hundred nanograms of RNA were used for 
cDNA synthesis using an iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA, USA). For PCR, 10 µl iQ SYBR 
green, 7 µl water, and 1 µl of 250 nM primer solution 
were added to 2 µl of a cDNA sample. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and ribosomal 
protein lateral stalk subunit P0 (RPLP0) were used as 
housekeeping genes. The primer sequences appear in 
Supplementary Table 5.
Microscopic and histomorphometric analysis
Stained sections were studied using a Leica 
DM6000 B/M light microscope connected to a digital 
camera (DFC420; Leica Microsystems).
The invasion area, which represents the total surface 
area of the invaded cancer cells excluding the surface non-
invading cells, and depth were calculated using ImageJ 
software (Wayne Rasband, National Institute of Mental 
Health, Bethesda, MD, USA) as described previously 
[11]. The number of CD45+ and CD8+ T cells was 
calculated from at least three selected fields (10 or 20X 
magnification), which showed the highest infiltration for 
each slide. The percentage of Ki67+ cells was calculated 
from at least three randomly selected fields of the non-
invading cells (on the myoma surface).
Statistical analysis
All experiments were repeated independently three 
to eight times, each in duplicate or triplicate. Values are 
given as means ± standard deviations. To determine the 
statistical significance, we performed one-way analysis 
of variance (ANOVA) followed by Tukey’s post-hoc test. 
We set statistical significance to P < 0.05. Correlations 
between cell proliferation, the invasion area, and depth 
were determined using the Pearson’s correlation test.
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